

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.  
2503-1033

SERIAL NO.  
10/009,501

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

APPLICANT  
Josee GOLAY et al.

FILING DATE  
May 6, 2002

GROUP  
1644

37 CFR 1.98(b)

**U.S. PATENT DOCUMENTS**

		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						

**FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION**

		DOCUMENT NO.	PUBL. DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANSLATION YES NO
	AC						
	AD						

**OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)**

AE	McLaughlin, Peter et al., "Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program", <u>Journal of Clinical Oncology</u> , Vol. 16, pp. 2825-2833. XP-002149247
AF	
AG	
AH	
AI	
AJ	

**EXAMINER**

**DATE CONSIDERED**

**EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

